Anti-Cancer Chemotherapy for Colorectal Cancer - RETIRED | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its anti-cancer chemotherapy coverage policy for colorectal cancer, effective April 24, 2026, retiring the existing policy. Here's what billing teams need to do.

This change removes an active CMS coverage policy governing anti-cancer chemotherapy for colorectal cancer from the policy library. The policy does not list specific codes in the available documentation. Given the volume of colorectal cancer claims billed to Medicare every year, a retired policy at the CMS level carries real financial exposure for oncology and infusion billing teams.

CMS Anti-Cancer Chemotherapy for Colorectal Cancer Coverage Criteria and Medical Necessity Requirements 2026

The CMS anti-cancer chemotherapy for colorectal cancer coverage policy is being retired as of April 24, 2026. What that means practically: the national coverage determination or policy document that once served as your primary billing authority for these services is going away.

This does not automatically mean chemotherapy for colorectal cancer loses Medicare reimbursement. What it means is that the specific policy document CMS used to define medical necessity criteria for these services will no longer exist as an active reference.

When a coverage policy at the national level retires, coverage authority typically falls down to the Medicare Administrative Contractor level. Your MAC — whether that's Novitas, CGS, WPS, or another contractor — may have a local coverage determination that fills this gap. Check your MAC's LCD library immediately. Don't assume coverage continues unchanged just because services are still being rendered.

Prior authorization requirements for chemotherapy under Medicare have been evolving, and the retirement of a national policy can sometimes trigger new prior auth workflows at the MAC level. Confirm with your MAC whether prior authorization applies to the specific regimens your practice bills. Do that before the effective date of April 24, 2026.

The real issue here is medical necessity documentation. When a CMS coverage policy retires, the specific clinical criteria that once anchored your documentation requirements may no longer apply — or new criteria from your MAC's LCD may replace them. Your clinical documentation must align with whatever criteria now govern coverage. If your templates were built around the retired policy's language, update them now.

What a Retired CMS Policy Actually Means for Colorectal Cancer Chemotherapy Billing

A policy retirement is not the same as a coverage denial. It's easy to conflate the two, but they're different. Retirement means CMS is pulling the specific policy document — the rules that codified which regimens, diagnoses, and clinical scenarios qualified for Medicare reimbursement under this framework.

Coverage for colorectal cancer chemotherapy may continue under other authority. But "may continue" is not the same as "will continue without any action on your part." Your billing team cannot afford to assume the status quo holds.

Think of this like Aetna's 2024 shift on genetic testing coverage — the procedure didn't disappear from coverage, but the governing policy changed, and practices that didn't update their documentation workflows saw a spike in claim denial activity. The same risk exists here.

Colorectal cancer is one of the most common cancer diagnoses billed to Medicare. The reimbursement dollars at stake across infusion centers, oncology practices, and hospital outpatient departments are significant. A disruption in the coverage policy framework — even a temporary one while MAC-level coverage is confirmed — creates direct financial exposure.

CMS Colorectal Cancer Chemotherapy Exclusions and Non-Covered Indications

The available policy documentation does not specify exclusions or non-covered indications in the retired policy. That's actually a problem, not a relief.

When a policy retires without a replacement document clearly delineating what's covered and what isn't, billing teams are left without a definitive exclusion list. You don't know what the new fence looks like until you find the new boundary documents.

This ambiguity is exactly when claim denial risk rises. If your MAC's LCD contains exclusions that the retiring CMS policy did not — or vice versa — claims that sailed through before April 24, 2026 may not after. Audit your recent claims against your MAC's current LCD language before the effective date.

If you're not sure how this applies to your payer mix or your specific regimen portfolio, talk to your compliance officer before April 24, 2026.

Coverage Indications at a Glance

The policy data does not include specific indication-level coverage criteria. The table below reflects the information available from the policy retirement notice.

CMS Colorectal Cancer Chemotherapy Billing Guidelines and Action Items 2026

These are the steps your billing team needs to take before April 24, 2026. Don't treat this as a monitoring item. Treat it as a project with a deadline.

CPT, HCPCS, and ICD-10 Codes for Anti-Cancer Chemotherapy for Colorectal Cancer Under This Policy

The policy data for this retirement notice does not include specific CPT, HCPCS, or ICD-10 codes. This is not unusual for a retirement notice — the original policy document may have referenced codes that are no longer listed in the retirement record.

Do not use this absence as a signal that no codes are affected. Anti-cancer chemotherapy for colorectal cancer involves a broad range of billing codes across drug administration, injectable agents, and diagnosis coding. The retirement of this policy likely touches a significant code set.

Your MAC's LCD will specify the CPT and HCPCS codes it governs. That is where you find your definitive code list after the effective date of April 24, 2026. Pull those codes and cross-reference them against your charge capture.

If you need the historical code set from the original CMS policy, request it directly from CMS or your MAC. Don't reconstruct it from memory or assumption.